Group items matching

in title, tags, annotations or url

More than 10,000 pharmacy contractors those have declared their March FP34C submission figures through the Manage Your Service (MYS) portal by 5 April will receive earlier advance payments on Monday 11 April, the NHS Business Services Authority (NHSBSA) announced. Around 10,700 pharmacy contractors have made their submissions through MYS portal. They will receive their advance payments some 20 days earlier than the normal payment timetable. However, due to late submission (after April 5), over 500 contractors will not receive any earlier advance payments in April. These contractors will receive their advance payments on 1 May, in accordance with the normal payment timetable. From this month, MYS is the only route available to contractors for all monthly FP34C submissions. The Pharmaceutical Services Negotiating Committee (PSNC) reminded contractors that from this month (for prescriptions dispensed in March), the NHSBSA may apply an administrative deduction of £25 if a prescription bundle is submitted late.

I have always been passionate about Community Pharmacy and am proud of the way that the sector navigated itself through Covid-19 and is currently navigating itself through all the changes in the NHS landscape. When I started my role in Sep 2019 as the CEO of Kent LPC, I used to say that community pharmacy has changed more in the last five years than the 15 before that, however, I now believe community pharmacy has changed more in the last two years than the 20 before. The year 2019 saw the start of the five-year Community Pharmacy Contractual Framework which set out how community pharmacy would support delivery of the NHS long term plan. What PSNC (or any of us) when negotiating this deal had not envisaged was the Covid-19 pandemic. Whilst the world turned upside down, we saw high street shops close their doors and immense pressure flood the NHS. Community pharmacy did what they always do, they adapted, teams came together, worked through, and showed resilience in the face of adversity. In Kent, I saw us integrate into primary are and into the NHS structure very quickly, in the first few weeks after Covid-19. All the usual red tape was removed, we all worked together to implement services to help patients in a matter of weeks when they would have normally taken months.

With so much hype about DNA testing, people are more than interested in buying a home dna test kit and finding out about their ancestry. The truth about DNA testing is that they reveal more than one's ancestral background. Primarily, DNA testing was used to detect criminals or prove the innocence of someone awaiting capital punishment. Today, things have changed, and DNA-related things are no more revolving around criminal justice alone. Genetic science can reveal the following amazing things: FIND OUT YOUR FAMILY TREE DNA testing has helped people map their family tree and find out details about who their forefathers were and which regions of the world they were from. Believe us or not, but it is the right time to go for it now if you have never performed a DNA test before! Just choose the right DNA testing kit to connect with the previously unknown branches of your family. DNA testing has increased in popularity as people live a more conscientious life. Today, everyone is looking for answers regarding their genetic ethnicity and how they can live a happier and healthier life.

GSK Consumer Healthcare has recently unveiled a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care. The new report summarises findings from a roundtable hosted by GSK Consumer Healthcare in collaboration with the International Pharmaceutical Federation (FIP) earlier this year, which convened the pharmacy community, policy experts, and industry leaders to discuss the critical role of pharmacy in the age of self-care following the Covid-19 pandemic. "We've seen Covid-19 have a significant impact on consumers' understanding of self-care, leading to an increased focus on wellbeing and everyday healthcare. During this time, pharmacies played a vital role in providing care and advice to their patients - particularly with many other health facilities closed. Our research shows that more than half of Europeans are planning to consult their pharmacist more often than before the pandemic. Yet in general, pharmacists remain under-utilised, despite being the most widely distributed health resource in Europe," said Tess Player, global head of expert at GSK Consumer Healthcare.

Future pandemics could be even more lethal than Covid-19 so the lessons learned from the outbreak must not be squandered and the world must ensure it is prepared for the next viral onslaught, one of the creators of the Oxford-AstraZeneca vaccine said. "The truth is, the next one could be worse. It could be more contagious, or more lethal, or both," Prof Dame Sarah Gilbert said in the Richard Dimbleby Lecture, the BBC reported. "This will not be the last time a virus threatens our lives and our livelihoods." Gilbert, a professor of vaccinology at the University of Oxford, said the world should make sure it is better prepared for the next virus. "The advances we have made, and the knowledge we have gained, must not be lost," she said. Efforts to end the Covid-19 pandemic have been uneven and fragmented, marked by limited access to vaccines in low-income countries while the "healthy and wealthy" in rich countries get boosters, health experts say.

A Nottingham-based pharmacist has been struck off the General Pharmaceutical Council (GPhC) register for bringing "the profession into to disrepute" by stealing hundreds of thousands of pounds in a bid to settle his gambling debt. Peter Sameh Saad (33) spun a web of lies and duped a friend out of more than half a million pounds to fund his addiction and pretended he had "serious if not terminal" testicular cancer. "It is difficult to imagine a more heinous fraud than one predicated on feigning a cancer diagnosis", a GPC panel ruled. Saad committed three frauds on a total of £536,689.95 between September 2018 and May 2019. First, he tricked a friend, whom he knew through his local church, into sending him around £288,200 by claiming that his newly-purchased pharmacy in US was "seized" by the authorities over visa issues and that he "had some difficulty making the mortgage payments". Later Saad conned the same friend, named only as 'Person A' in court documents, into sending him a total of £127,150 by lying about a non-existent cancer diagnosis and private treatment. Finally, he extracted a further £121,339.95 from an investments and credit group (named Company A) of which his friend was chief executive after inviting him to set up a 'pharmaceutical warehouse', a plan that "impressed Person A and he agreed to invest in the business."

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS. Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic. "Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year," said NHS. In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease. More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.

In a recent survey of 2,000 UK adults, 34 per cent preferred consulting pharmacists for health advice after researching symptoms, while for those surveyed specifically from Wales, this figure increased to 35 per cent, according to 2San - a global supplier of healthcare products and solutions. The survey said women had a higher tendency, with 39 per cent seeking their pharmacist's guidance compared to 29 per cent of men surveyed. According to the survey findings, over one-fifth of people in the UK are turning to pharmacists instead of their primary care physician or doctor for guidance and advice with medical symptoms. "With more than 38 million patients in the UK waiting more than two weeks for a GP appointment, it is unsurprising that 34 per cent of people surveyed asked a pharmacist for advice over their primary care physician/doctor in the last 12 months," 2san said. In Wales, over a third of people prefer their community pharmacist for support and advice, while those aged 65 and above still tend to consult their primary care physician.

Advanz Pharma, alongside London-based private equity firms Cinven and HgCapital, is collectively confronted with an £84 million penalty for inflating the price of the thyroid drug by over 1,000 per cent, soaring from £20 to £248 per package over an eight-year period. The Competition Appeal Tribunal endorsed 'all key aspects' of the Competition and Markets Authority's verdict on the companies' culpability in the case, the CMA has said. Advanz stood as the sole supplier of liothyronine tablets, essential for treating thyroid hormone deficiency, with the cost of a packet of these tablets surging over 12-fold between 2009 and 2017. Although Advanz Pharma currently possesses ownership of the company, its former owners, PE firms Cinven and HgCapital, also bear responsibility for the imposed fine, the CMA said. "NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016," Britain's competition watchdog said.

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

Data crunched by an online pharmacy delivery company paints a concerning picture for the pharmacy sector in England. Gophr's 'Prescription For Pressure' initiative reveals a challenging time for the sector and is supported by separate analysis by the BBC showing that the number of pharmacies in England is at its lowest since 2010. In addition, new powers being introduced for pharmacists to prescribe common prescription drugs and perform routine tests create an even greater workload for already overstretched pharmacists. Gophr's data reveals that: * Each pharmacy in England serves an average of 6,078 people. * In 2022, pharmacists dispensed 1.043 billion prescriptions, 26.3 million more than 2021. * A single pharmacy in England dispensed 248 prescriptions a day on average in 2022. Based on the most up-to-date statistics from the Office for National Statistics, NHS England and Statista, Gophr's calculations show that pharmacists have around 116 seconds to dispense a prescription, which is less time than the 180 seconds it takes to make a Quarter Pounder at McDonald's.

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men. NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over 40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes could be prevented this year thanks to the high street checks." "The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added. Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart attacks and strokes each month.

Despite a 13 per cent increase from last year, less than a quarter (21%) of pharmacy teams recommend Proton Pump Inhibitors (PPIs) as a first line of treatment for frequent heartburn. There has been a 4% decrease in pharmacy teams considering 'frequent heartburn' as a condition that occurs more than once a week 8-in-10 said a larger pack size would be useful to their patients who suffer from frequent heartburn. Haleon, formerly part of GSK, has recently commissioned research to better understand how pharmacy teams help patients to treat frequent heartburn. Comparing with data captured last year, there has been a been a +13% increase in the number of pharmacy teams recommending Proton Pump Inhibitors (PPIs) (21% in 2022 vs 8% in 2021). Nexium Control, the UK's number one heartburn product for 24-hour protection, aims to use this research to provide better support for pharmacists and their teams and encourage the recommendation of PPIs, where appropriate for frequent heartburn, over other heartburn remedies.

More than 100 species of turmeric exist today, and one common feature is their yellowish-orange tint. Curcuminoids are the compounds that give this color to turmeric. Turmeric has three main curcuminoids, which make up 2-6% of the rhizome content, and out f these three, curcumin has the highest share, up to 80%. For example, the powdered turmeric spice for cooking has, on average, 1-3% or 1-3 grams f curcumin per 100 grams. Curcumin is turmeric's bioactive element that treats people's health conditions t the cellular level. The Latin name for turmeric is Curcuma longa. But what are the differences between curcuma longa, turmeric, and curcumin? In this article, you'll find the following in detail: *Curcumin versus Turmeric *Potential Health Benefits of Turmeric and Curcumin *Health Benefits of Turmeric *Curcumin may be more valuable than Turmeric for particular reasons. *Which is best?

Boots pharmacists will receive a pay rise of 4.5 per cent as the pharmacy multiple and PDA Union jointly announce this year's pay settlement. Following discussions between Boots management services and the PDA Union negotiators, the agreement was reached in relation to this year's pay claim, effective from 1 November 2022. The union also announced that those who have already had a pay increase on or since 1 August 2022, where that increase has been less than 4.5 per cent, a 'top up' increase will be provided, from 1 November 2022, to ensure that all eligible members of the bargaining unit receive a pay increment of not less than 4.5 per cent in 2022. Boots and the PDA Union have agreed an increase to the pay of those above the maximum market range by 4 per cent with an additional 0.5 per cent non-consolidated payment.

Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men, particularly during and after the menopause. According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from the condition, but only once they have had the symptoms of dry eye syndrome described to them. Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be. Causes of dry eye Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated, dry eyes can even lead to long-term damage and sight problems. Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye. However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers: fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers can cause dry eyes.

Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering "everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain management by focusing on the acute pain recovery journey. Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain. The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in alleviating their pain. The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2]. This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets. Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".

HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer. The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022. David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products. He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business. "I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level."